Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
NCT ID: NCT06731270
Last Updated: 2025-06-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
20 participants
INTERVENTIONAL
2025-04-09
2027-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer
NCT03121417
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
NCT03600701
Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer
NCT04348292
Etirinotecan Pegol (NKTR-102) in NSCLC
NCT01773109
Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
NCT01721759
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To evaluate the clinical benefit rate of concomitant diclofenac potassium (diclofenac) and single agent checkpoint blockade.
SECONDARY OBJECTIVES:
I. To evaluate the safety and tolerability of concomitant diclofenac and single agent checkpoint blockade.
II. To evaluate the efficacy of concomitant diclofenac and single agent checkpoint blockade in NSCLC.
EXPLORATORY OBJECTIVES:
I. To evaluate the change in immunophenotype in circulating CD8 T cells following initiation of diclofenac oral therapy in patients who show early sings of progression on single agent immunotherapy for advanced lung cancer.
II. To investigate the role of PD-L1 expression status in response to the addition of diclofenac daily oral therapy in patients who show early sings of progression on single agent immunotherapy for advanced lung cancer.
III. To evaluate the role of serum lactic acid levels in determining dose exposure to diclofenac.
IV. To evaluate the change in circulating immune parameters (CD4 T cells and B cells) with the addition of diclofenac to single agent immunotherapy.
V. To evaluate the role of the tumor microenvironment at the time of diagnosis on efficacy.
OUTLINE:
Patients receive diclofenac orally (PO) twice daily (BID) and standard of care immunotherapy with pembrolizumab, atezolizumab, nivolumab or cemiplimab on day 1 of each cycle. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and computed tomography (CT), positron emission tomography (PET), or magnetic resonance imaging (MRI) on study.
After completion of study treatment, patients are followed up every 12 weeks for up to 1 year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (diclofenac, immunotherapy)
Patients receive diclofenac PO BID and standard of care immunotherapy with pembrolizumab, atezolizumab, nivolumab or cemiplimab on day 1 of each cycle. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and CT, PET, or MRI on study.
Atezolizumab
Given atezolizumab
Biospecimen Collection
Undergo blood sample collection
Cemiplimab
Given cemiplimab
Computed Tomography
Undergo CT
Diclofenac Potassium
Given PO
Electronic Health Record Review
Ancillary studies
Magnetic Resonance Imaging
Undergo MRI
Nivolumab
Given nivolumab
Pembrolizumab
Given pembrolizumab
Positron Emission Tomography
Undergo PET
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atezolizumab
Given atezolizumab
Biospecimen Collection
Undergo blood sample collection
Cemiplimab
Given cemiplimab
Computed Tomography
Undergo CT
Diclofenac Potassium
Given PO
Electronic Health Record Review
Ancillary studies
Magnetic Resonance Imaging
Undergo MRI
Nivolumab
Given nivolumab
Pembrolizumab
Given pembrolizumab
Positron Emission Tomography
Undergo PET
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years at time of study entry
* Stage III or IV pathologically proven NSCLC with advanced or metastatic disease, currently on treatment with an Food and Drug Administration (FDA) approved single agent monoclonal antibody inhibiting the PD(L)-1 pathway (pembrolizumab, atezolizumab, nivolumab, or cemiplimab) for a minimum of 12 weeks
* May include frontline single agent immune checkpoint inhibitors (ICI), maintenance single agent ICI after chemo-ICI, or subsequent line therapy
* Radiographic evidence of clinical progression as determined by the treating physician, not warranting immediate change of therapy. Progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria is not required. This can include mixed response, will need at least one growing lesion. Exposure to PD1 inhibitor for at least 12 weeks will minimize the risk of pseudo-progression
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Life expectancy of ≥ 26 weeks
* Absolute neutrophil count (ANC) ≥ 1,000 cell/mm\^3
* Platelets ≥ 100,000 cells/mm\^3
* Hemoglobin ≥ 8 gm/dL
* Creatinine clearance ≥ 45 ml/ml
* Bilirubin ≤ 1.5 x institutional upper limit of normal
* Bilirubin must be ≤ 3 x institutional upper limit of normal in patients with documented Gilbert's syndrome
* Serum glutamic oxaloacetic transaminase (SGOT) / serum gluatmic pyruvic transaminase (SGPT) ≤ 2.5 x institutional upper limit of normal
* Ability to take oral medications
* Willingness and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
Exclusion Criteria
* Prophylactic or therapeutic anticoagulation therapy including but not limited to: warfarin, heparin, low molecular weight heparin, or direct oral anticoagulants, including: dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa)
* Treatment within the previous 6 weeks or planned initiation of bevacizumab
* Abnormal markers of coagulation as measured by international normalized ratio (INR) \> 2
* Contraindication for NSAID therapy including: chronic aspirin therapy for coronary artery disease (CAD), cerebrovascular accident (CVA), or other indication, uncontrolled gastrointestinal ulcerative disease, known bleeding diathesis, known allergy or hypersensitivity to NSAIDS, advanced renal disease, uncontrolled hypertension, known seizure disorder or others
* Female of childbearing potential unwilling or unable to use 2 methods of contraception, detailed in protocol
* Uncontrolled intercurrent illness
* History of another primary malignancy with exceptions noted in protocol
* History of active primary immunodeficiency or active infection including tuberculosis, hepatitis B, hepatitis C
* Current or prior use of immunosuppressive medication within 14 days before the first dose of diclofenac. There are exceptions to this criterion
* Receipt of live attenuated vaccine within 30 days prior to the first dose of study medications
* Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Emory University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jennifer Carlisle
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jennifer W Carlisle
Role: PRINCIPAL_INVESTIGATOR
Emory University Hospital/Winship Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Emory University Hospital Midtown
Atlanta, Georgia, United States
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2024-07760
Identifier Type: REGISTRY
Identifier Source: secondary_id
STUDY00006572
Identifier Type: OTHER
Identifier Source: secondary_id
Winship6018-23
Identifier Type: OTHER
Identifier Source: secondary_id
STUDY00006572
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.